Kyoto, Japan

Kazuya Otake

USPTO Granted Patents = 1 

Average Co-Inventor Count = 13.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kazuya Otake: Innovator in Medicinal Chemistry

Introduction

Kazuya Otake is a prominent inventor based in Kyoto, Japan. He is recognized for his contributions to medicinal chemistry, particularly in the development of compounds that address diseases associated with oxidative stress. His innovative work has led to significant advancements in the field of pharmacology.

Latest Patents

Otake holds a patent for a benzotriazole compound aimed at treating and preventing diseases linked to oxidative stress. The invention focuses on inhibiting the protein-protein interaction between Keap1 and Nrf2, thereby activating Nrf2. This compound is represented by a specific formula and includes pharmaceutically acceptable salts. The medicament developed from this compound is intended for the prophylaxis and treatment of various diseases, including chronic kidney disease, non-alcoholic steatohepatitis, and Parkinson's disease, among others.

Career Highlights

Throughout his career, Kazuya Otake has worked with notable companies such as Daiichi Sankyo Company, Limited and Kyoto Pharmaceutical Industries, Ltd. His experience in these organizations has contributed to his expertise in drug development and medicinal research.

Collaborations

Otake has collaborated with esteemed colleagues, including Yoshihiro Ogura and Rieko Takano. These partnerships have fostered a collaborative environment that enhances innovation and research in medicinal chemistry.

Conclusion

Kazuya Otake's work in developing a benzotriazole compound showcases his commitment to addressing critical health issues through innovative solutions. His contributions to the field of medicinal chemistry continue to have a lasting impact on the treatment of diseases associated with oxidative stress.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…